Coherus Oncology, Inc. (CHRS)
NASDAQ: CHRS · Real-Time Price · USD
1.500
+0.020 (1.35%)
Jun 26, 2026, 4:00 PM EDT - Market closed
Coherus Oncology Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 21.83 | 42.17 | 26.39 | 257.24 | 211.04 | 326.55 | |
Revenue Growth (YoY) | 33.50% | 59.81% | -89.74% | 21.89% | -35.37% | -31.37% |
Cost of Revenue | 7.12 | 13.81 | 8.73 | 158.99 | 70.08 | 57.59 |
Gross Profit | 14.71 | 28.36 | 17.66 | 98.25 | 140.96 | 268.96 |
Selling, General & Admin | 50.97 | 100.6 | 125.48 | 192.02 | 198.48 | 169.71 |
Research & Development | 106.08 | 108.89 | 91.83 | 109.44 | 199.36 | 363.11 |
Total Operating Expenses | 157.05 | 209.49 | 217.32 | 301.45 | 397.84 | 532.82 |
Operating Income | -89.82 | -181.13 | -199.65 | -203.2 | -256.88 | -263.86 |
Interest Expense | -4.6 | -9 | -10.73 | -40.54 | -32.47 | -22.96 |
Other Non-Operating Income (Expense) | 5.04 | 7.01 | -5.01 | 5.47 | -2.4 | -0.28 |
Total Non-Operating Income (Expense) | 0.44 | -1.99 | -15.74 | -35.07 | -34.87 | -23.24 |
Pretax Income | -172.66 | -183.12 | -215.39 | -238.27 | -291.75 | -287.1 |
Provision for Income Taxes | - | - | - | -0.38 | - | - |
Net Income | 186.27 | 168.02 | 28.51 | -237.89 | -291.75 | -287.1 |
Earnings From Discontinued Operations | 358.93 | 351.15 | 243.9 | - | - | - |
Net Income to Common | 545.19 | 519.17 | 272.41 | -237.89 | -291.75 | -287.1 |
Net Income Growth | - | 90.59% | - | - | - | - |
Shares Outstanding (Basic) | 122 | 117 | 115 | 94 | 78 | 75 |
Shares Outstanding (Diluted) | 122 | 117 | 115 | 94 | 78 | 75 |
Shares Change (YoY) | 6.02% | 2.26% | 21.66% | 21.30% | 2.89% | -9.63% |
EPS (Basic) | -1.29 | 1.43 | 0.25 | -2.53 | -3.76 | -3.81 |
EPS (Diluted) | -1.29 | 1.43 | 0.25 | -2.53 | -3.76 | -3.81 |
EPS Growth | - | 472.00% | - | - | - | - |
Free Cash Flow | -170.57 | -138.51 | -20.44 | -174.88 | -241.12 | -38.72 |
Free Cash Flow Per Share | -1.40 | -1.18 | -0.18 | -1.86 | -3.11 | -0.51 |
Gross Margin | 67.40% | 67.24% | 66.93% | 38.19% | 66.79% | 82.36% |
Operating Margin | -411.54% | -429.51% | -756.58% | -78.99% | -121.72% | -80.80% |
Profit Margin | 853.45% | 398.43% | 108.03% | -92.48% | -138.25% | -87.92% |
FCF Margin | -781.55% | -328.45% | -77.46% | -67.98% | -114.25% | -11.86% |
EBITDA | -86.06 | -177.21 | -194.38 | -199.41 | -253.18 | -260.4 |
EBITDA Margin | -394.32% | -420.21% | -736.58% | -77.52% | -119.97% | -79.74% |
EBIT | -89.82 | -181.13 | -199.65 | -203.2 | -256.88 | -263.86 |
EBIT Margin | -411.54% | -429.51% | -756.58% | -78.99% | -121.72% | -80.80% |
Effective Tax Rate | - | 0.00% | 0.00% | 0.16% | 0.00% | 0.00% |